Patents by Inventor Chris Steele

Chris Steele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20250340526
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: July 10, 2025
    Publication date: November 6, 2025
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele, Grace Uzoho
  • Pyridazinone compounds and uses thereof
    Patent number: 12415794
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: September 16, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele, Grace Uzoho
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20250223278
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: December 13, 2024
    Publication date: July 10, 2025
    Inventors: Kevin Hunt, Kevin Koch, Alan James Russell, Stephen Thomas Schlachter, Paul Winship, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 12240833
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Grace Uzoho, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 12240831
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: March 4, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 12202819
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: January 21, 2025
    Assignee: EDGEWISE THERAPEUTICS, INC.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 12012395
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: June 18, 2024
    Assignee: Edgewise Therapeutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20240025879
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • Pyridazinone compounds and uses thereof
    Patent number: 11873290
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: January 16, 2024
    Assignee: Edgewise Therapeutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20230048816
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: May 27, 2022
    Publication date: February 16, 2023
    Inventors: Kevin HUNT, Kevin KOCH, Alan RUSSELL, Stephen SCHLACHTER, Paul WINSHIP, Grace UZOHO, Chris STEELE
  • Pyridazinone compounds and uses thereof
    Patent number: 11390606
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: July 19, 2022
    Assignee: Edgewise Therapecutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Grace Uzoho, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220106291
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: June 11, 2021
    Publication date: April 7, 2022
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220081410
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 23, 2021
    Publication date: March 17, 2022
    Inventors: Kevin HUNT, Kevin KOCH, Alan RUSSELL, Stephen SCHLACHTER, Paul WINSHIP, Chris STEELE, Grace UZOHO
  • Pyridazinone compounds and uses thereof
    Patent number: 11236065
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: February 1, 2022
    Assignee: Edgewise Therapecutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele, Grace Uzoho
  • Pyridazinone compounds and uses thereof
    Patent number: 11091464
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: August 17, 2021
    Assignee: Edgewise Therapeutics, Inc.
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20210188814
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 3, 2020
    Publication date: June 24, 2021
    Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Chris Steele
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20210179579
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 3, 2020
    Publication date: June 17, 2021
    Inventors: Kevin HUNT, Kevin KOCH, Alan RUSSELL, Stephen SCHLACHTER, Paul WINSHIP, Chris STEELE, Grace UZOHO
  • PYRIDAZINONE COMPOUNDS AND USES THEREOF
    Publication number: 20210130327
    Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.
    Type: Application
    Filed: November 3, 2020
    Publication date: May 6, 2021
    Inventors: Kevin HUNT, Kevin KOCH, Alan RUSSELL, Stephen SCHLACHTER, Paul WINSHIP, Grace UZOHO, Chris STEELE
  • Fused triazole derivatives as gamma secretase modulators
    Patent number: 9527853
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: December 27, 2016
    Assignee: Ares Trading S.A.
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher
  • FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
    Publication number: 20150183790
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Application
    Filed: June 14, 2013
    Publication date: July 2, 2015
    Applicant: Merck Patent GmbH
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher